At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma.
ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma
23rd July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?